SMTE-001

SMTE-001: sourced facts only. name: "We designed SMTE-001, a 78-kDa, tetra-specific, T-cell-activating protein molecule, which binds to two epitopes (membrane proximal and membrane distal) of MSLN, CD3ε on T cells, and to serum albumin." [DOI:10.1158/1538-7445.am2022-6343]; target: "We designed SMTE-001, a 78-kDa, tetra-specific, T-cell-activating protein molecule, which binds to two epitopes (membrane proximal and membrane distal) of MSLN, CD3ε on T cells, and to serum albumin." [DOI:10.1158/1538-7445.am2022-6343]; target: "We designed SMTE-001, a 78-kDa, tetra-specific, T-cell-activating protein molecule, which binds to two epitopes (membrane proximal and membrane distal) of MSLN, CD3ε on T cells, and to serum albumin." [DOI:10.1158/1538-7445.am2022-6343]; developer: "1Jiangsu Simcere Pharmaceutical Co. Ltd., Nanjing, Jiangsu, China, China." [DOI:10.1158/1538-7445.am2022-6343]; stage: "Importantly, we demonstrate in vivo that SMTE-001 significantly inhibits tumor growth in a dose-dependent manner, while high-affinity CD3 molecule’ efficacy reduces when higher dosing." [DOI:10.1158/1538-7445.am2022-6343]